Clinical trials: Moderate Plaque Psoriasis
Psoriasis
Study of Secukinumab With 2 mL Pre-filled Syringes
The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.
- Trial name
- ALLURE (NCT02748863)
- Testing
- Secukinumab 2 mL form, Secukinumab 1 mL form
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 214 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
- Trial name
- BE CARING (NCT06888193)
- Testing
- Bimekizumab
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 20 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
CP-690-550 Ointment For Chronic Plaque Psoriasis
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
- Trial name
- NCT01246583
- Testing
- CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- Pfizer
Plaque Psoriasis
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
- Trial name
- CLARITY (NCT02826603)
- Testing
- Secukinumab, Ustekinumab
- Where
- 154 sites in United States, Canada and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07672561
- Testing
- Drug:WD-890
- Where
- China
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Moderate to Severe Chronic Plaque Psoriasis
Community Based Trial for AMEVIVE®
To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.
- Trial name
- NCT00168753
- Testing
- Alefacept
- Where
- 36 sites in United States
- Volunteers
- 114 people
- Sponsor
- Astellas Pharma Inc
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Psoriatic Arthritis
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin.
- Trial name
- NCT04433442
- Where
- 63 sites in South Korea
- Volunteers
- 2,324 people
- Sponsor
- AbbVie
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer
Moderate to Severe Chronic Plaque Psoriasis
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
- Trial name
- NCT01758705
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis
This study is open to adults with plaque psoriasis. The main purpose of this study is to find out whether people with plaque psoriasis can tolerate a medicine called BI 765250.
- Trial name
- NCT05728489
- Testing
- BI 765250
- Where
- 5 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study of Ixekizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam)…
- Trial name
- NCT02993471
- Testing
- Drug Cocktail, Ixekizumab
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Plaque-type Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
- Trial name
- NCT00773734
- Testing
- Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg
- Where
- 35 sites in United States, Canada
- Volunteers
- 352 people
- Sponsor
- Amgen
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).
- Trial name
- NCT03000075
- Testing
- risankizumab
- Volunteers
- 182 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment…
- Trial name
- MECAP (NCT07129382)
- Testing
- CS32582 capsule（low dose）, CS32582 capsule（medium dose）, CS32582 capsule（high dose）
- Where
- 11 sites in China
- Volunteers
- 220 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Psoriasis
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
REALIZE study will include a representative sample of 500 patients with moderate to severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label…
- Trial name
- REALIZE (NCT03757013)
- Testing
- Apremilast
- Where
- 93 sites in France
- Volunteers
- 453 people
- Sponsor
- Amgen
Plaque Psoriasis
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
The purpose of this trial is to investigate the efficacy and safety of different doses and dose administrations of FP187 compared to a placebo treatment in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01230138
- Testing
- FP187
- Where
- 2 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Forward-Pharma GmbH
Plaque Psoriasis
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT04607980
- Testing
- ABP 654, Ustekinumab
- Where
- 84 sites in United States, Canada and 6 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Psoriasis
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of guselkumab on coronary flow reserve (CFR), measured by transthoracic doppler-echocardiography, in participants with moderate-to-severe psoriasis and intermediate…
- Trial name
- G-CARE (NCT05125679)
- Testing
- Guselkumab
- Where
- 5 sites in Germany, Greece and 1 more
- Volunteers
- 15 people
- Sponsor
- Janssen-Cilag Ltd.
Psoriasis, Plaque Psoriasis
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an…
- Trial name
- NCT05725057
- Testing
- AX-158
- Where
- 6 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Artax Biopharma Inc